| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
AAV-Mediated Artificial miRNA Reduces Pathogenic Polyglucosan Bodies and Neuroinflammation in Adult Polyglucosan Body and Lafora Disease Mouse Models
|
Gumusgoz, Emrah
|
|
|
19 |
3 |
p. 982-993
|
article
|
| 2 |
AAV-Mediated Artificial miRNA Reduces Pathogenic Polyglucosan Bodies and Neuroinflammation in Adult Polyglucosan Body and Lafora Disease Mouse Models
|
Gumusgoz, Emrah
|
|
|
19 |
3 |
p. 982-993
|
article
|
| 3 |
A Brain-Penetrant Stearoyl-CoA Desaturase Inhibitor Reverses α-Synuclein Toxicity
|
Nuber, Silke
|
|
|
19 |
3 |
p. 1018-1036
|
article
|
| 4 |
A Brain-Penetrant Stearoyl-CoA Desaturase Inhibitor Reverses α-Synuclein Toxicity
|
Nuber, Silke
|
|
|
19 |
3 |
p. 1018-1036
|
article
|
| 5 |
Antibody Therapies for Progressive Multiple Sclerosis and for Promoting Repair
|
Havla, Joachim
|
|
|
19 |
3 |
p. 774-784
|
article
|
| 6 |
Antibody Therapies for Progressive Multiple Sclerosis and for Promoting Repair
|
Havla, Joachim
|
|
|
19 |
3 |
p. 774-784
|
article
|
| 7 |
Antibody Therapies in Autoimmune Encephalitis
|
Smets, I.
|
|
|
19 |
3 |
p. 823-831
|
article
|
| 8 |
Antibody Therapies in Autoimmune Encephalitis
|
Smets, I.
|
|
|
19 |
3 |
p. 823-831
|
article
|
| 9 |
Antibody Therapies in Autoimmune Inflammatory Myopathies: Promising Treatment Options
|
Zeng, Rachel
|
|
|
19 |
3 |
p. 911-921
|
article
|
| 10 |
Antibody Therapies in Autoimmune Inflammatory Myopathies: Promising Treatment Options
|
Zeng, Rachel
|
|
|
19 |
3 |
p. 911-921
|
article
|
| 11 |
Antibody Therapies in Autoimmune Neuromuscular Junction Disorders: Approach to Myasthenic Crisis and Chronic Management
|
Vanoli, Fiammetta
|
|
|
19 |
3 |
p. 897-910
|
article
|
| 12 |
Antibody Therapies in Autoimmune Neuromuscular Junction Disorders: Approach to Myasthenic Crisis and Chronic Management
|
Vanoli, Fiammetta
|
|
|
19 |
3 |
p. 897-910
|
article
|
| 13 |
Anti-complement Agents for Autoimmune Neurological Disease
|
McCombe, Jennifer A.
|
|
|
19 |
3 |
p. 711-728
|
article
|
| 14 |
Anti-complement Agents for Autoimmune Neurological Disease
|
McCombe, Jennifer A.
|
|
|
19 |
3 |
p. 711-728
|
article
|
| 15 |
Autoimmune Neurological Disorders with IgG4 Antibodies: a Distinct Disease Spectrum with Unique IgG4 Functions Responding to Anti-B Cell Therapies
|
Dalakas, Marinos C.
|
|
|
19 |
3 |
p. 741-752
|
article
|
| 16 |
Autoimmune Neurological Disorders with IgG4 Antibodies: a Distinct Disease Spectrum with Unique IgG4 Functions Responding to Anti-B Cell Therapies
|
Dalakas, Marinos C.
|
|
|
19 |
3 |
p. 741-752
|
article
|
| 17 |
Bezafibrate Rescues Mitochondrial Encephalopathy in Mice via Induction of Daily Torpor and Hypometabolic State
|
Lyu, Jingwei
|
|
|
19 |
3 |
p. 994-1006
|
article
|
| 18 |
Bezafibrate Rescues Mitochondrial Encephalopathy in Mice via Induction of Daily Torpor and Hypometabolic State
|
Lyu, Jingwei
|
|
|
19 |
3 |
p. 994-1006
|
article
|
| 19 |
CRISPR-Cas9 Gene Therapy for Duchenne Muscular Dystrophy
|
Happi Mbakam, Cedric
|
|
|
19 |
3 |
p. 931-941
|
article
|
| 20 |
CRISPR-Cas9 Gene Therapy for Duchenne Muscular Dystrophy
|
Happi Mbakam, Cedric
|
|
|
19 |
3 |
p. 931-941
|
article
|
| 21 |
Current Chemical, Biological, and Physiological Views in the Development of Successful Brain-Targeted Pharmaceutics
|
Markowicz-Piasecka, Magdalena
|
|
|
19 |
3 |
p. 942-976
|
article
|
| 22 |
Current Chemical, Biological, and Physiological Views in the Development of Successful Brain-Targeted Pharmaceutics
|
Markowicz-Piasecka, Magdalena
|
|
|
19 |
3 |
p. 942-976
|
article
|
| 23 |
Evolution of Anti-B Cell Therapeutics in Autoimmune Neurological Diseases
|
Stathopoulos, Panos
|
|
|
19 |
3 |
p. 691-710
|
article
|
| 24 |
Evolution of Anti-B Cell Therapeutics in Autoimmune Neurological Diseases
|
Stathopoulos, Panos
|
|
|
19 |
3 |
p. 691-710
|
article
|
| 25 |
Immunoglobulin and Monoclonal Antibody Therapies in Guillain-Barré Syndrome
|
Rajabally, Yusuf A.
|
|
|
19 |
3 |
p. 885-896
|
article
|
| 26 |
Immunoglobulin and Monoclonal Antibody Therapies in Guillain-Barré Syndrome
|
Rajabally, Yusuf A.
|
|
|
19 |
3 |
p. 885-896
|
article
|
| 27 |
Low-Dose Ziprasidone in Combination with Sertraline for First-Episode Drug-Naïve Patients with Schizophrenia: a Randomized Controlled Trial
|
Zhu, Cheng
|
|
|
19 |
3 |
p. 1037-1046
|
article
|
| 28 |
Low-Dose Ziprasidone in Combination with Sertraline for First-Episode Drug-Naïve Patients with Schizophrenia: a Randomized Controlled Trial
|
Zhu, Cheng
|
|
|
19 |
3 |
p. 1037-1046
|
article
|
| 29 |
Monoclonal Antibodies in the Treatment of Relapsing Multiple Sclerosis: an Overview with Emphasis on Pregnancy, Vaccination, and Risk Management
|
Krajnc, Nik
|
|
|
19 |
3 |
p. 753-773
|
article
|
| 30 |
Monoclonal Antibodies in the Treatment of Relapsing Multiple Sclerosis: an Overview with Emphasis on Pregnancy, Vaccination, and Risk Management
|
Krajnc, Nik
|
|
|
19 |
3 |
p. 753-773
|
article
|
| 31 |
Monoclonal Antibody Therapies Beyond Complement for NMOSD and MOGAD
|
Redenbaugh, Vyanka
|
|
|
19 |
3 |
p. 808-822
|
article
|
| 32 |
Monoclonal Antibody Therapies Beyond Complement for NMOSD and MOGAD
|
Redenbaugh, Vyanka
|
|
|
19 |
3 |
p. 808-822
|
article
|
| 33 |
Neonatal Fc Receptor–Targeted Therapies in Neurology
|
Nelke, Christopher
|
|
|
19 |
3 |
p. 729-740
|
article
|
| 34 |
Neonatal Fc Receptor–Targeted Therapies in Neurology
|
Nelke, Christopher
|
|
|
19 |
3 |
p. 729-740
|
article
|
| 35 |
Nervonic Acid Attenuates Accumulation of Very Long-Chain Fatty Acids and is a Potential Therapy for Adrenoleukodystrophy
|
Terluk, Marcia R.
|
|
|
19 |
3 |
p. 1007-1017
|
article
|
| 36 |
Nervonic Acid Attenuates Accumulation of Very Long-Chain Fatty Acids and is a Potential Therapy for Adrenoleukodystrophy
|
Terluk, Marcia R.
|
|
|
19 |
3 |
p. 1007-1017
|
article
|
| 37 |
Paraneoplastic Autoimmune Neurological Syndromes and the Role of Immune Checkpoint Inhibitors
|
Duong, Sophie L.
|
|
|
19 |
3 |
p. 848-863
|
article
|
| 38 |
Paraneoplastic Autoimmune Neurological Syndromes and the Role of Immune Checkpoint Inhibitors
|
Duong, Sophie L.
|
|
|
19 |
3 |
p. 848-863
|
article
|
| 39 |
Stiff-person Syndrome and GAD Antibody-spectrum Disorders: GABAergic Neuronal Excitability, Immunopathogenesis and Update on Antibody Therapies
|
Dalakas, Marinos C.
|
|
|
19 |
3 |
p. 832-847
|
article
|
| 40 |
Stiff-person Syndrome and GAD Antibody-spectrum Disorders: GABAergic Neuronal Excitability, Immunopathogenesis and Update on Antibody Therapies
|
Dalakas, Marinos C.
|
|
|
19 |
3 |
p. 832-847
|
article
|
| 41 |
The Arrival of Anti-CGRP Monoclonal Antibodies in Migraine
|
Cohen, Fred
|
|
|
19 |
3 |
p. 922-930
|
article
|
| 42 |
The Arrival of Anti-CGRP Monoclonal Antibodies in Migraine
|
Cohen, Fred
|
|
|
19 |
3 |
p. 922-930
|
article
|
| 43 |
Therapeutic Antibodies in Neurological Diseases: Witnessing the Continuation of the Impressive Success in Neuro-Immunotherapies
|
Dalakas, Marinos C.
|
|
|
19 |
3 |
p. 687-690
|
article
|
| 44 |
Therapeutic Antibodies in Neurological Diseases: Witnessing the Continuation of the Impressive Success in Neuro-Immunotherapies
|
Dalakas, Marinos C.
|
|
|
19 |
3 |
p. 687-690
|
article
|
| 45 |
Therapeutic Monoclonal Antibody Therapies in Chronic Autoimmune Demyelinating Neuropathies
|
Briani, Chiara
|
|
|
19 |
3 |
p. 874-884
|
article
|
| 46 |
Therapeutic Monoclonal Antibody Therapies in Chronic Autoimmune Demyelinating Neuropathies
|
Briani, Chiara
|
|
|
19 |
3 |
p. 874-884
|
article
|
| 47 |
The Role of the Complement System in Chronic Inflammatory Demyelinating Polyneuropathy: Implications for Complement-Targeted Therapies
|
Querol, Luis A.
|
|
|
19 |
3 |
p. 864-873
|
article
|
| 48 |
The Role of the Complement System in Chronic Inflammatory Demyelinating Polyneuropathy: Implications for Complement-Targeted Therapies
|
Querol, Luis A.
|
|
|
19 |
3 |
p. 864-873
|
article
|
| 49 |
Two Diseases—One Preclinical Treatment Targeting Glycogen Synthesis
|
Gentry, Matthew S.
|
|
|
19 |
3 |
p. 977-981
|
article
|
| 50 |
Two Diseases—One Preclinical Treatment Targeting Glycogen Synthesis
|
Gentry, Matthew S.
|
|
|
19 |
3 |
p. 977-981
|
article
|
| 51 |
What Have Failed, Interrupted, and Withdrawn Antibody Therapies in Multiple Sclerosis Taught Us?
|
Krämer, Julia
|
|
|
19 |
3 |
p. 785-807
|
article
|
| 52 |
What Have Failed, Interrupted, and Withdrawn Antibody Therapies in Multiple Sclerosis Taught Us?
|
Krämer, Julia
|
|
|
19 |
3 |
p. 785-807
|
article
|
Journal description